TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15206657

Group type: EXPERIMENTAL
Intervention: Fluvoxamine CR (100-300 mg/d)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 11467241

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 95

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Salbutamol and Theophylline
Number of subjects: 95
Study: 9571327

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg once nightly for 8 weeks, 20 mg for the next 8 weeks, and 40 mg for the third 8-week period)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily throughout the 24 weeks)
Number of subjects: 96
Study: 7849231

Group type: EXPERIMENTAL
Intervention: 300 mg R(‐)‐ibuprofen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg S(+)‐ibuprofen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg R(‐)(‐)+300 mg S(+)‐ibuprofen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg R(‐)(‐)+600 mg S(+)‐ibuprofen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study: 2468859

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg b.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Captopril (50 mg b.i.d.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg q.d.) + Captopril (25 mg b.i.d.)
Number of subjects: 30
Study: 31574881

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous adductor canal block (ACB)
Number of subjects: 0
Study: 27558768

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.0‐1.5 g/day for 6 months, then 0.5‐0.75 g/day for another 6 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 60
Study: 25886930

Group type: EXPERIMENTAL
Intervention: Integrated services (ANC, prevention of mother-to-child transmission, and HIV care delivered in the ANC clinic)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Standard ANC services (including prevention of mother-to-child transmission and referral to a separate clinic for HIV care)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Integrated services
Number of subjects: 611

Group type: COMPARATOR
Intervention: Standard ANC services
Number of subjects: 611
Study: 23538168

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once a day for 7 days
Number of subjects: 346

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once a day for 7 days
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Prulifloxacin
Number of subjects: 346

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 346
Study: 21329626

Group type: EXPERIMENTAL
Intervention: Extended-release (ER) dexibuprofen (450 mg, b.i.d.)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Immediate-release (IR) dexibuprofen (300 mg, t.i.d.)
Number of subjects: 22
Study: 19118394

Group type: EXPERIMENTAL
Intervention: Computer-mediated intervention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17728965

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Naproxen sodium 550 mg
Number of subjects: 60
Study: 16623000

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 100 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 120
Study: 12452208

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment (Budesonide and Terbutaline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9652764

Group type: COMPARATOR
Intervention: FAC regimen (5-fluorouracil 600 mg/m² i.v. over 1 h on days 1, 2, 3; doxorubicin 50 mg/m² i.v. bolus on day 1; cyclophosphamide 400 mg/m² i.v. bolus on days 1, 2, 3)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: FULON regimen (5-fluorouracil 250 mg/m² day(-1) continuously infused from day 1 to day 22; doxorubicin 15 mg/m² i.v. bolus on days 1, 8, 15, 22; cyclophosphamide 300 mg/m² i.v. bolus on days 1, 8, 15, 22)
Number of subjects: 258
Study: 7661127

Group type: EXPERIMENTAL
Intervention: High-fat diet + Alcohol
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-fat diet + Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-fat diet + Alcohol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-fat diet + Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High alcohol intake
Number of subjects: 8
Study: 2667882

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (1 hour, 3 times a week for 8 weeks)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nonaerobic exercise (1 hour, 3 times a week for 8 weeks)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both aerobic and nonaerobic exercise
Number of subjects: 99
Study: 336135

Group type: EXPERIMENTAL
Intervention: Carbohydrate restriction with phenformin (50 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate restriction without phenformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypotensive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypolipidaemic treatment (supplemented when necessary)
Number of subjects: 0
Study: 29294732

Group type: EXPERIMENTAL
Intervention: Individual Cognitive-Behavioral Therapy (ICBT) for 20 sessions
Number of subjects: 42

Group type: COMPARATOR
Intervention: Group Cognitive-Behavioral Therapy (GCBT) for 20 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Group Cognitive-Behavioral Therapy (GCBT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Individual Cognitive-Behavioral Therapy (ICBT)
Number of subjects: 42
Study: 31724347

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 97

Group type: COMPARATOR
Intervention: Western medication (flunarizine hydrochloride capsule, 5 mg once a day)
Number of subjects: 97
Study: 28615506

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 159

Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 159
Study: 25228446

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 23813194

Group type: EXPERIMENTAL
Intervention: PROMPT treatment with TKP cues
Number of subjects: 4

Group type: COMPARATOR
Intervention: PROMPT treatment without TKP cues
Number of subjects: 4
Study: 21477425

Group type: EXPERIMENTAL
Intervention: CDX-947 (solubilized budesonide)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: CDX-313 (solubilized azelastine + budesonide)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Suspension-type comparators (budesonide [Rhinocort Aqua] or azelastine + budesonide [Astelin] + Rhinocort Aqua)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 18648229

Group type: EXPERIMENTAL
Intervention: Droperidol (1 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Droperidol (1 mg) + Ondansetron (4 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17050796

Group type: EXPERIMENTAL
Intervention: Digoxin (0.5 mg oral) administered individually
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Midazolam (2.0 mg oral) administered individually
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Coadministration of digoxin (1 hour after midazolam)
Number of subjects: 14
Study: 15041987

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Transobturator suburethral tape (T.O.T.)
Number of subjects: 61
Study: 10588635

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice a day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Seratrodast (80 mg once a day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Seratrodast
Number of subjects: 9
Study: 7847430

Group type: EXPERIMENTAL
Intervention: Plasma glucose level at 2.2 mmol/L
Number of subjects: 42

Group type: COMPARATOR
Intervention: Plasma glucose level at 8.9 mmol/L
Number of subjects: 42

Group type: COMPARATOR
Intervention: Plasma glucose levels (14.4 and 21.1 mmol/L)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Gender (Women)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Gender (Men)
Number of subjects: 42
Study: 2114625

Group type: EXPERIMENTAL
Intervention: Prophylactic administration of steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urokinase and no accompanying treatment
Number of subjects: 0
Study: 91499

Group type: EXPERIMENTAL
Intervention: Mental rotation of geometric forms
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Serial addition of a column of signed digits
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Substitution of letters with subsequent word recognition
Number of subjects: 32

Group type: COMPARATOR
Intervention: Visual fixation
Number of subjects: 32
Study: 30696682

Group type: EXPERIMENTAL
Intervention: Bortezomib add-on to pre-existing therapy
Number of subjects: 18
Study: 28902944

Group type: EXPERIMENTAL
Intervention: Shoelace group (n=35, catheter fixation using shoelace cross-tied sutures)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wing group (n=35, catheter fixation with clamping wings and retainers)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 23235719

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 22341199

Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Medication use reduction
Number of subjects: 322
Study: 19398689

Group type: EXPERIMENTAL
Intervention: Computerized medication reconciliation tool and process redesign
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (standard medication reconciliation process)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Computerized medication reconciliation tool and process redesign at hospital 1
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Computerized medication reconciliation tool and process redesign at hospital 2
Number of subjects: 322
Study: 17848682

Group type: EXPERIMENTAL
Intervention: Revascularization treatment
Number of subjects: 36
Study: 15976206

Group type: EXPERIMENTAL
Intervention: Ondansetron oral disintegrating tablets (4 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 12688134

Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg/day of hGH (biosynthetic human growth hormone‐‐Humatrope)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6 micrograms/kg/day of hGH (biosynthetic human growth hormone‐‐Humatrope)
Number of subjects: 10
Study: 9445311

Group type: EXPERIMENTAL
Intervention: Arrow 'Hands-Off' thermodilution catheter (AHO)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard thermodilution catheter (TC)
Number of subjects: 150
Study: 7616301

Group type: EXPERIMENTAL
Intervention: Beta-carotene (120 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: UV light exposure (three times the minimal erythema dose)
Number of subjects: 0
Study: 2377860

Group type: EXPERIMENTAL
Intervention: Soviet diagnostic criteria for osteoarthrosis
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: American diagnostic criteria for gonarthrosis
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Regression tree method
Number of subjects: 105
Study: 758129

Group type: EXPERIMENTAL
Intervention: RAO/LAO angiography
Number of subjects: 21

Group type: COMPARATOR
Intervention: AP/LAT angiography
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interobserver agreement
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Inter-method variability
Number of subjects: 21
Study: 31826959

Group type: EXPERIMENTAL
Intervention: Solana HSV 1+2/VZV assay
Number of subjects: 302

Group type: COMPARATOR
Intervention: Viral culture
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: RealStar PCR assay
Number of subjects: 302
Study: 30773500

Group type: EXPERIMENTAL
Intervention: Cavernous tissue–sparing technique
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 92
Study: 27765728

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 18113
Study: 24927225

Group type: EXPERIMENTAL
Intervention: Individualized outdoor activity intervention delivered by volunteers (once a week for three months)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Individualized outdoor activity intervention (for subgroups with minor depressive symptoms at baseline)
Number of subjects: 121
Study: 24490380

Group type: EXPERIMENTAL
Intervention: LVD 100 mg daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (routine colligative treatment only)
Number of subjects: 58
Study: 21342149

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's (LR) solution
Number of subjects: 104

Group type: COMPARATOR
Intervention: Plasmalyte
Number of subjects: 104
Study: 19401375

Group type: EXPERIMENTAL
Intervention: Morning meal size of 418 KJ
Number of subjects: 10

Group type: COMPARATOR
Intervention: Morning meal size of 2090 KJ
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise energy expenditure (2273 to 2361 KJ)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TPN energy replacement (1521 to 1538 KJ)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Midday ad libitum meal
Number of subjects: 10
Study: 17901191

Group type: EXPERIMENTAL
Intervention: Structured education and training program in ethics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17130190

Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil-SR (T/V)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Losartan/Hydrochlorothiazide (L/H)
Number of subjects: 240
Study: 12650165

Group type: EXPERIMENTAL
Intervention: Combination of acetylsalicylic acid (ASA) and clopidogrel
Number of subjects: 14330

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) alone
Number of subjects: 14330

Group type: EXPERIMENTAL
Intervention: Combination of ASA and ticlopidin
Number of subjects: 14330
Study: 10390287

Group type: EXPERIMENTAL
Intervention: Weekly low-dose vitamin A supplementation (10,000 IU)
Number of subjects: 400
Study: 1832824

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 25 micrograms
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 40 micrograms
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 55 micrograms
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 70 micrograms
Number of subjects: 41
Study: 6127780

Group type: EXPERIMENTAL
Intervention: KWD 2131 (beta-adrenoceptor stimulant)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 28715242

Group type: EXPERIMENTAL
Intervention: Omega-3 (Ω3)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Psychoeducational psychotherapy (PEP)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Active monitoring (AM)
Number of subjects: 95
Study: 28709466

Group type: EXPERIMENTAL
Intervention: 7% inhaled hypertonic saline (HS - 4 ml 7% sodium chloride)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline (NS - 0.9% sodium chloride)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (HS and NS)
Number of subjects: 12
Study: 26181507

Group type: EXPERIMENTAL
Intervention: Active rTMS (2000 pulses per session, 1-Hz daily for 10 consecutive workdays)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo rTMS (2000 pulses per session, 1-Hz daily for 10 consecutive workdays)
Number of subjects: 70
Study: 24494287

Group type: EXPERIMENTAL
Intervention: Wrist-ankle needle
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Body-acupuncture
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 95
Study: 21392075

Group type: EXPERIMENTAL
Intervention: Sirukumab (0.3, 1, 3, 6 or 10 mg kg(‐1) intravenous infusion)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 19634955

Group type: EXPERIMENTAL
Intervention: Seeking Safety (12 sessions, M = 6.2 sessions)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Women's Health Education (WHE) (12 sessions, M = 6.0 sessions)
Number of subjects: 353
Study: 17295917

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate
Number of subjects: 4
Study: 14686958

Group type: EXPERIMENTAL
Intervention: HRT (Kliofem)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 11136497

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ticlopidine 200 mg/d
Number of subjects: 130
Study: 9576148

Group type: EXPERIMENTAL
Intervention: High-serum-ECP group (serum level of ECP > 15.7 ng/mL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-serum-ECP group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Serum concentration of ECP
Number of subjects: 80
Study: 7935656

Group type: EXPERIMENTAL
Intervention: Troglitazone, 200 mg orally twice daily for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 18
Study: 3229016

Group type: EXPERIMENTAL
Intervention: Grapefruit pectin supplementation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30638547

Group type: EXPERIMENTAL
Intervention: Intraventricular fibrinolysis (IVF)
Number of subjects: 440

Group type: COMPARATOR
Intervention: External ventricular drainage (EVD) alone
Number of subjects: 440
Study: 28370637

Group type: EXPERIMENTAL
Intervention: Single-use negative pressure wound therapy (sNPWT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard care (film dressings of clinician choice)
Number of subjects: 220
Study: 25800762

Group type: EXPERIMENTAL
Intervention: Early palliative care intervention (three structured weekly telephone coaching sessions, monthly follow‐up, and a bereavement call)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Delayed palliative care intervention (three structured weekly telephone coaching sessions, monthly follow‐up, and a bereavement call starting 3 months after enrollment)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Early palliative care intervention (in decedents' CGs)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Delayed palliative care intervention (in decedents' CGs)
Number of subjects: 122
Study: 23699748

Group type: EXPERIMENTAL
Intervention: Life Smart (two classes; N = 51)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (three usual classes; N = 64)
Number of subjects: 115
Study: 20972608

Group type: EXPERIMENTAL
Intervention: Screening intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19472307

Group type: EXPERIMENTAL
Intervention: Selection criteria for working correlation structures in GEE analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-based and sandwich-based estimator of covariance matrix
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted error sum of squares minimization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rule out criteria for estimated correlation parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive definiteness of estimated correlation structure
Number of subjects: 0
Study: 17290041

Group type: EXPERIMENTAL
Intervention: Tailored asthma management program
Number of subjects: 314

Group type: COMPARATOR
Intervention: Generic asthma websites (control)
Number of subjects: 314
Study: 15549973

Group type: EXPERIMENTAL
Intervention: Magill position (a pillow under the occiput and the head extended)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Manual in‐line position (without a pillow under the occiput)
Number of subjects: 21
Study: 12115394

Group type: EXPERIMENTAL
Intervention: L-758,298 100 mg i.v. + dexamethasone 20 mg i.v. + cisplatin >or= 70 mg/m(2) + MK-869 300 mg orally on Days 2-5
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: L-758,298 100 mg i.v. + dexamethasone 20 mg i.v. + cisplatin >or= 70 mg/m(2) + placebo on Days 2-5
Number of subjects: 177

Group type: COMPARATOR
Intervention: ondansetron 32 mg i.v. + dexamethasone 20 mg i.v. + cisplatin >or= 70 mg/m(2) + placebo on Days 2-5
Number of subjects: 177
Study: 10470656

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR (1200 mg/day) administered for more than 5 days before operation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no preoperative chemotherapy)
Number of subjects: 46
Study: 8682234

Group type: EXPERIMENTAL
Intervention: 10 mcg/Kg of atropine in 60 seconds (Group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 15 mcg/Kg of atropine in 120 seconds (Group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 mcg/Kg of atropine in 120 seconds (Group 3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 mcg/Kg of atropine in 120 seconds (Group 4, with full-dose oral beta-blocker therapy)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atropine effect on HR and R-R interval in resting conditions (60 patients, 15 from each group)
Number of subjects: 100
Study: 2243886

Group type: EXPERIMENTAL
Intervention: DMI plus propranolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: DMI
Number of subjects: 16
Study: 352473

Group type: EXPERIMENTAL
Intervention: Day care (discharged directly home)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Convalescent hospital (48 hours)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Acute ward (48 hours)
Number of subjects: 360
Study: 31901783

Group type: EXPERIMENTAL
Intervention: Cryotherapy using a frozen glove (FG) for 60 minutes
Number of subjects: 38

Group type: COMPARATOR
Intervention: Compression therapy using a surgical glove (SG) for 90 minutes
Number of subjects: 38